Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jun 21;11(6):862.
doi: 10.3390/cancers11060862.

Cancer Stem Cells and Radioresistance: DNA Repair and Beyond

Affiliations
Review

Cancer Stem Cells and Radioresistance: DNA Repair and Beyond

Alexander Schulz et al. Cancers (Basel). .

Abstract

The current preclinical and clinical findings demonstrate that, in addition to the conventional clinical and pathological indicators that have a prognostic value in radiation oncology, the number of cancer stem cells (CSCs) and their inherent radioresistance are important parameters for local control after radiotherapy. In this review, we discuss the molecular mechanisms of CSC radioresistance attributable to DNA repair mechanisms and the development of CSC-targeted therapies for tumor radiosensitization. We also discuss the current challenges in preclinical and translational CSC research including the high inter- and intratumoral heterogeneity, plasticity of CSCs, and microenvironment-stimulated tumor cell reprogramming.

Keywords: 5Rs of radiation biology; DNA repair; cancer stem cells; radioresistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
The general mechanisms of cancer stem cell (CSC) radioresistance. Many protective mechanisms are activated in CSCs that result in treatment resistance. These include intrinsic determinants (activation of the pro-survival pathways, enhanced DNA repair capability, protection against oxidative stress, unlimited self-renewal potential, impaired cell cycle arrest, and apoptosis) and extrinsic determinants such as hypoxic microenvironment and a protective CSC niche consisting of the cellular components (e.g., non-CSCs, fibroblasts, immune cells, endothelial cells), soluble factors (e.g., growth factors, hormones and cytokines), and extracellular matrix. ATM—ataxia–telangiectasia mutated; ATR—ATM- and Rad3-Related; Chk1—checkpoint kinase 1; Chk2—checkpoint kinase 2; ECM—extracellular matrix; FAK—focal adhesion kinase; GSH—glutathione; JAK—Janus kinase; EGFR—epidermal growth factor receptor; HIF—hypoxia-inducible factor; PI3K—phosphatidylinositol 3-kinases; ROS—reactive oxygen species.
Figure 2
Figure 2
DNA repair pathways altered in CSCs are associated with DNA replication. Replication-associated DNA repair pathways leading to enhanced DNA repair (red) mediate resistance in CSCs, while further replication-associated DNA repair pathways remain unchanged (gray). Upregulation is based on increased expression (red) or increased activation (yellow) or both (red/yellow) and is supported by regulatory proteins (gray). BER—base excision repair; FA—Fanconi anemia; HR—homologous recombination; NER—nucleotide excision repair; NHEJ—non-homologous end joining; MMR—mismatch repair; PR—proof reading; TLS—translesion synthesis [9,68,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85].

References

    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv. Nutr. 2016;7:418–419. doi: 10.3945/an.116.012211. - DOI - PMC - PubMed
    1. Bray F., Jemal A., Grey N., Ferlay J., Forman D. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol. 2012;13:790–801. doi: 10.1016/S1470-2045(12)70211-5. - DOI - PubMed
    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C., Dicker D., Pain A., Hamavid H., Moradi-Lakeh M., MacIntyre M.F., Allen C., Hansen G., Woodbrook R., et al. The Global Burden of Cancer 2013. JAMA Oncol. 2015;1:505–527. doi: 10.1001/jamaoncol.2015.0735. - DOI - PMC - PubMed
    1. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Pineros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2018 doi: 10.1002/ijc.31937. - DOI - PubMed

LinkOut - more resources